Integral Molecular's MAbs against CB1 to treat NASH enter new development phase following $1.4 million award

(Integral Molecular) Integral Molecular, the industry leader in antibody discovery against multipass membrane proteins, was awarded $1.4 million by the NIH to develop its lead antibodies against cannabinoid receptor 1 (CB1) for treating the liver disease nonalcoholic steatohepatitis (NASH) and metabolic disorders, including obesity and metabolic syndrome. With this Phase 2 SBIR grant, Integral Molecular builds on its successful Phase 1 SBIR program isolating antibodies with high specificity and high affinity for CB1.
Source: EurekAlert! - Biology - Category: Biology Source Type: news

Related Links:

This study aimed to investigate the effects of a 12-week multicomponent intervention program in markers of metabolic syndrome and NAFLD in Brazilian overweight/obese low-income school-aged children.MethodsThis quasi-experimental study comprised overweight/obese school-aged children, aged 7 –13 years. The participants were assigned to intervention (n = 17) or control group (n = 18). The multicomponent intervention was developed during 12 weeks, consisting of exercise sessions (twice/week; 1 h), nutritional education sessions (once/month), and parental support (twice/week). The fol...
Source: Sport Sciences for Health - Category: Sports Medicine Source Type: research
Metabolic syndrome, characterized by central obesity, hypertension, and hyperlipidemia, increases the morbidity and mortality of cardiovascular disease, type 2 diabetes, nonalcoholic fatty liver disease, and other metabolic diseases. It is well known that insulin resistance, especially hepatic insulin resistance, is a risk factor for metabolic syndrome. Current research has shown that hepatic fatty acid accumulation can cause hepatic insulin resistance through increased gluconeogenesis, lipogenesis, chronic inflammation, oxidative stress and endoplasmic reticulum stress, and impaired insulin signal pathway. Mitochondria ar...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
CONCLUSION: In this study, we demonstrate that risk factors for NAFLD and LF in the IBD population do not differ from those in the general population. PMID: 31602167 [PubMed - in process]
Source: World Journal of Gastroenterology : WJG - Category: Gastroenterology Authors: Tags: World J Gastroenterol Source Type: research
Obesity and its complications, which affect myriad organ systems, continue to be major worldwide public health problems in adults and children.1 Nonalcoholic fatty liver disease (NAFLD) is associated with obesity and the metabolic syndrome that encompasses insulin resistance, dyslipidemia, and hypertension. The prevalence of NAFLD in children varies widely and is dependent on the method of diagnosis, age, sex, and ethnicity, but the estimated global prevalence is 7.6% in the general pediatric population and 34.2% in obese children.
Source: The Journal of Pediatrics - Category: Pediatrics Authors: Tags: Editorial Source Type: research
Nonalcoholic fatty liver disease (NAFLD) is estimated to affect up to one-third of the general population, and new therapies are urgently required. Our laboratory previously developed a controlled-release mitochondrial protonophore (CRMP) that is functionally liver-targeted and promotes oxidation of hepatic triglycerides. Although we previously demonstrated that CRMP safely reverses hypertriglyceridemia, fatty liver, hepatic inflammation, and fibrosis in diet-induced rodent models of obesity, there remains a critical need to assess its safety and efficacy in a model highly relevant to humans. Here, we evaluated the impact ...
Source: Science Translational Medicine - Category: Biomedical Science Authors: Tags: Research Articles Source Type: research
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research
CONCLUSION: Despite some limitations of our study, such as the small number of patients, and the use of two different methods of evaluation (biopsy and elastography), the data obtained allow us to conclude that of the 39 evaluated cases, 33% (13) presented progression of fibrosis and the total group of 50 patients, 42% had cirrhosis or died due to liver disease. The presence of NASH on hepatic biopsy did not prove to be, in our study, a predictive of the evolution of hepatic fibrosis in the patients.RESUMO CONTEXTO: A doen ça hepática gordurosa não alcoólica vem sendo diagnosticada com frequ&eci...
Source: Arquivos de Gastroenterologia - Category: Gastroenterology Source Type: research
EchoSens creates non-invasive liver diagnosis medical devices. The company’s line of products, called FibroScan, work by measuring the speed of ultrasound waves as they move through liver tissue. This measurement can tell us about the state of ...
Source: Medgadget - Category: Medical Devices Authors: Tags: Diagnostics Exclusive GI Medicine Source Type: blogs
Authors: Dong Y, Li G Abstract Nonalcoholic fatty liver disease (NAFLD) is one of the most common forms of chronic liver disease in developed countries and is associated with type 2 diabetes mellitus, obesity, hypertension, dyslipidemia, and metabolic syndrome. It is defined as steatosis in over 5% of hepatocytes. The disease spectrum of NAFLD ranges from simple fatty liver to nonalcoholic steatohepatitis, liver fibrosis, even hepatic cirrhosis. The disease affects various extra-hepatic systems such as the cardiovascular system and urinary system. Heart-related disease is identified as the leading cause of mor...
Source: Herz - Category: Cardiology Tags: Herz Source Type: research
The objective of this review is to present the evidence for DILI and hepatotoxicity mechanisms, incidence, and outcomes in patients with MetS and nonalcoholic fatty liver disease. Moreover, we also summarize the relationships between drugs used to treat metabolic comorbidities and DILI. PMID: 31531370 [PubMed - in process]
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
More News: Biology | Eating Disorders & Weight Management | Grants | Liver | Liver Disease | Metabolic Syndrome | Molecular Biology | Obesity | Urology & Nephrology